In life sciences, enterprise value only emerges when generative AI is treated as a business capability and embedded into existing operating models.

In recent years, generative AI (GenAI) has become a prominent topic of discussion in life sciences. However, I often hear from my life science clients about the need for more clarity around its actual ...

Dealmaking in the life sciences sector took a major hit in 2022: the year was one of the lowest recorded years by value since 2017, with only $105 billion in merger and acquisition (M&A) deals ...